Document is current
Any future updates will be listed below
-
Authors
Neumair, Matthias
Kattan, Michael W.
Freedland, Stephen J.
Haese, Alexander
Guerrios-Rivera, Lourdes
De Hoedt, Amanda M.
Liss, Michael A.
Leach, Robin J.
Boorjian, Stephen A.
Cooperberg, Matthew R.
Poyet, Cedric
Saba, Karim
Herkommer, Kathleen
Meissner, Valentin H.
Vickers, Andrew J.
Ankerst, Donna P.
-
Funding
Funding for this research was provided by:
US National Institutes of Health (CA179115, CA179115, CA179115, CA179115, CA179115, P30 CA054174, CA179115, CA179115, CA179115, CA179115, CA179115, CA179115)
Technische Universität München
- License Information
-
More Information
Article History
Received: 3 December 2021
Accepted: 4 July 2022
First Online: 21 July 2022
Declarations
:
: PBCG data were collected following IRB approval at UT Health San Antonio, Memorial Sloan Kettering Cancer Center, Mayo Clinic, University of Zurich, VA Durham, VA Caribbean Healthcare System San Juan, P.R., VA Durham, San Raffaele Hospital, Sunnybrook Health Systems, University of California San Francisco, Hamburg University Hospital. Analyses on anonymized data for this study were approved by the Technical University of Munich Ethics Commission. Consent was waived for all data collection, which involved only record extraction of standard clinical care elements. For detailed family history collected at the Durham VA written consent was obtained by all participants as required for a local study prior to this study.
: Not applicable.
: Andrew Vickers receives royalties from the 4Kscore, a test used in prostate cancer. He owns stock options in Opko, which offers the test. All other authors declare that they have no conflict of interest.
